Kangabio key facts
- Researcher and developer of drugs intend to serve the pharmaceutical industry.
- It has raised $29.9M; the latest was Early Stage VC ($15.0M) in Dec 2025.
- Notable investors include Teda VC, Taikun Fund, BOHE Angel Fund, Daoyuan Capital.
- Status: Privately Held (backing).
Who backs Kangabio
4- ·Watch Kangabio: the Monday email on marks, rounds and moves
Kangabio funding rounds
No funding rounds for Kangabio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Kangabio investors
4 investors are on record for Kangabio, including Teda VC, Taikun Fund, BOHE Angel Fund and Daoyuan Capital.
About Kangabio
Researcher and developer of drugs intend to serve the pharmaceutical industry. The company is mainly focused on the research and development of clinical drug discovery and includes innovative prodrug molecules for immune agonists and multispecific antibodies, providing clients with potential treatment with less toxicity.
- Sector
- Healthcare
- HQ
- Shanghai, China
- Founded
- 2021
- Website
- kangabio.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.
Kangabio doesn't have a valuation on record yet — one is published once a priced round, a reported valuation, fund marks, or secondary prints surface in our sources. The rest of the record below builds toward it.